Pulesa-uganda-strengthening the blood pressure care and treatment cascade for ugandans living with HIV-implementation strategies to save lives
Ended Cooperative Agreement Awarded Last action
- Award ID
- UH3HL154501
- Recipient
-
Infectious Diseases Research Collaboration UEI KEWUKWPQSYH9
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,494,653
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Uganda
Award details come from USAspending.gov.
Description
- Abstract
- Chronic HIV infection is a well-established risk factor for cardiovascular disease. In sub-saharan africa)-a region that may account for half of the global burden of CVD attributable to HIV-hypertension is the most important driver of CVD risk. Profound barriers to effective hypertension management exist, including limited knowledge, inconsistent BP measurement, and poor access to medications. HIV care innovations such as access to no-cost antiretroviral therapy, differentiated service delivery and use of plhiv peers in care models may improve care of comorbid conditions such as hypertension. The overarching goal of pulesa-uganda study is to improve the BP treatment cascade for people living with HIV (plhiv) in urban and peri-urban uganda in a scalable and sustainable manner. This hybrid is type 3 study proposes to first explore current practice, routines, barriers, and facilitators of evidence-based BP care in HIV clinical settings in kampala and wakiso districts (aim 1). Then, using a human-centered design approach, a design team of key stakeholders will use data from the formative assessment to develop a multi-component implementation strategy (HTN-plus) to improve uptake and adherence to evidence-based BP treatments, contextually adapted to these ugandan HIV clinics (sub-aim 1.1). The design team will adapt differentiated service delivery models, use of hypertensive plhiv peer champions, and methods of BP monitoring that address specific barriers and facilitators of BP care. In a stepped-wedge cluster randomized trial of 16 clinics from kampala and wakiso, we will determine the effectiveness of implementation strategies to improve BP cascade metrics (aim 2). Clinics will be randomized to receive free and consistent access to diagnostic equipment and evidence-based antihypertensive drugs (HTN-basic) with and without the multi-component implementation strategy developed in sub-aim 1 (HTN-plus). The primary effectiveness outcome will be % of patients with hypertension diagnosis who are controlled (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $732,384 | |
| Amendment | $1,300 | |
| Amendment | $1,300 | |
| Amendment | $505,164 | |
| Amendment | $505,164 | |
| Amendment | $1,300 | |
| Amendment | $1,300 | |
| Amendment | $1,300 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $742,841 | |
| Amendment | $1,300 | |
| Original award | $1,300 |
Show all 20
Quick answers
Who received award UH3HL154501?
UH3HL154501 was awarded to Infectious Diseases Research Collaboration by National Heart Lung and Blood Institute (National Institutes of Health) on September 10, 2020.
How much is award UH3HL154501 worth?
$2,494,653 has been obligated on UH3HL154501.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award